Molecular docking based screening analysis of GSK3B.
In this study we report the contribution and prognostic significance of GSK3B to two breast cancer subtypes; ductal carcinoma in-situ (DCIS) and invasive ductal carcinoma (IDC) using the Oncomine platform. We performed high throughput screening using molecular docking. We identified BT-000775, a compound that was subjected to further computational hit optimization protocols. Through computational predictions, BT-000775 is a highly selective GSK3B inhibitor, with superior binding affinity and robust ADME profiles suitable for the patho-physiological presentations.
PMID: 31354196 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Ogunleye AJ, Olanrewaju AJ, Arowosegbe M, Omotuyi OI Tags: Bioinformation Source Type: research
More News: Alzheimer's | Bioinformatics | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Diabetes | Diabetes Type 2 | Ductal Carcinoma | Endocrinology | Study